KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Neogenomics (NEO) over the last 17 years, with Q3 2025 value amounting to $8.3 million.

  • Neogenomics' Capital Expenditures fell 2301.14% to $8.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.7 million, marking a year-over-year decrease of 1583.56%. This contributed to the annual value of $41.1 million for FY2024, which is 4281.09% up from last year.
  • Per Neogenomics' latest filing, its Capital Expenditures stood at $8.3 million for Q3 2025, which was down 2301.14% from $6.3 million recorded in Q2 2025.
  • Over the past 5 years, Neogenomics' Capital Expenditures peaked at $21.3 million during Q2 2021, and registered a low of $4.3 million during Q3 2023.
  • In the last 5 years, Neogenomics' Capital Expenditures had a median value of $8.3 million in 2025 and averaged $9.7 million.
  • In the last 5 years, Neogenomics' Capital Expenditures skyrocketed by 32473.14% in 2021 and then tumbled by 6217.57% in 2022.
  • Over the past 5 years, Neogenomics' Capital Expenditures (Quarter) stood at $12.0 million in 2021, then crashed by 62.18% to $4.5 million in 2022, then soared by 55.65% to $7.1 million in 2023, then skyrocketed by 64.36% to $11.6 million in 2024, then dropped by 28.32% to $8.3 million in 2025.
  • Its Capital Expenditures was $8.3 million in Q3 2025, compared to $6.3 million in Q2 2025 and $4.5 million in Q1 2025.